<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766050</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-151</org_study_id>
    <nct_id>NCT01766050</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as &quot;Inje Cocktail&quot; in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of belatacept on the pharmacokinetics
      of caffeine, losartan, omeprazole, dextromethorphan and midazolam
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Systemic exposures of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam, measured by Maximum observed plasma concentration (Cmax), after single doses of the Inje Cocktail with and without the co administration of Belatacept</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposures of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam, measured by AUC(0-T), after single doses of the Inje Cocktail with and without the co administration of Belatacept</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC(0-T) = Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposures of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam, measured by AUC(INF), after single doses of the Inje Cocktail with and without the co administration of Belatacept</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7and 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC(INF) = Area under the plasma concentration-time curve from time zero extrapolated to infinite time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of 1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine after the single dose of the Inje Cocktail</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of 1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine after the single dose of the Inje Cocktail</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration [AUC(0-T)] of 1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine after the single dose of the Inje Cocktail</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine after the single dose of the Inje Cocktail</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of 1'-Hydroxy-Midazolam, E-3174, 5-Hydroxyomeprazole, Dextrorphan, and Paraxanthine after the single dose of the Inje Cocktail</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of the Inje cocktail components (Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of the Inje cocktail components (Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of the Inje cocktail components (Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Paraxanthine AUC(0-T) to Caffeine AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Paraxanthine AUC(INF) to Caffeine AUC(INF), corrected for molecular weight [MR_AUC(INF)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Paraxanthine (Cmax) to Caffeine (Cmax), corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of E-3174 AUC(0-T) to Losartan AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of E-3174 AUC(INF) to Losartan AUC(INF), corrected for molecular weight [MR_AUC(INF)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of E-3174 (Cmax) to Losartan (Cmax), corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Hydroxyomeprazole AUC(0-T) to Omeprazole AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Hydroxyomeprazole AUC(INF) to Omeprazole AUC(INF), corrected for molecular weight [MR_AUC(INF)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Hydroxyomeprazole (Cmax) to Omeprazole (Cmax), corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 5-Dextrorphan AUC(0-T) to Dextromethorphan AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 5-Dextrorphan AUC(INF) to Dextromethorphan AUC(INF), corrected for molecular weight [MR_AUC(INF)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 5-Dextrorphan (Cmax) to Dextromethorphan (Cmax), corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 1'-Hydroxy-Midazolam AUC(0-T) to Midazolam AUC(0-T), corrected for molecular weight [MR_AUC(0-T)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 1'-Hydroxy-Midazolam AUC(INF) to Midazolam AUC(INF), corrected for molecular weight [MR_AUC(INF)]</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 1'-Hydroxy-Midazolam (Cmax) to Midazolam (Cmax), corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>24 hours after dose of the Inje Cocktail on Days 1, 4, 7 and 11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of Adverse events (AEs), serious AEs, AEs leading to discontinuation, and death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, electrocardiograms (ECGs), and physical examinations</measure>
    <time_frame>Up to study discharge (Day 46Â±2)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11
Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <arm_group_label>Arm: Inje Cocktail + Belatacept</arm_group_label>
    <other_name>Nulojix</other_name>
    <other_name>BMS-224818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18 to 30 kg/m2

          -  Men and women ages 18 to 45

        Exclusion Criteria:

          -  Active tuberculosis

          -  Any recent infection requiring antibiotic treatment within 4 weeks of dosing

          -  Positive urine screen for drugs of abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, Llc D/B/A Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
